Danish companies — such as pharmaceutical giant Novo-Nordisk, who will get expanded patent protection in Canada — see huge opportunities for boosting their revenues through CETA.
The inclusion of intellectual property in the ongoing negotiations of the Regional Comprehensive Economic Partnership between 16 countries, most of them Asian, is raising concerns about “TRIPS-plus” measures that could jeopardise generic drugs production in India, according to Médecins Sans Frontières.
A leaked copy of the full text of the Canada-EU free trade agreement was posted online late Wednesday and appeared to confirm the fears of the deal’s critics on both sides of the Atlantic.
The Australian Medical Association (AMA) has urged the Australian government to reject provisions in the Trans Pacific Partnership agreement (TPP) that “could undermine the Pharmaceutical Benefits Scheme and compromise the ability of governments to improve public health”.
Peru’s National Association of Pharmaceutical Laboratories (Alafarpe) has filed a petition in the Peruvian courts to stop generic drugs from being sold based on the terms of US-Peru free trade agreement, according to Inca Kola News
The threat of the Transpacific Partnership Agreement to Australia’s Pharmaceutical Benefits Scheme is so real that Michael Moore, CEO of the Public Health Association of Australia, has said “It will cost Australian lives".
UNITAID, a global health initiative has warned against bilateral and regional trade agreements, pushed mostly by Europe and the US, as such agreements go well beyond traditional trade concerns and include provisions that force extensive obligations related to intellectual property and investor protection which would restrict access to medicines.
Ambitious free trade agreements in the Philippines would pose serious threats to access to medicines for the poor by providing greater patent rights to pharmaceutical companies, the EU-ASEAN Campaign Network said Tuesday ahead of an international meeting of pharmaceutical companies in Manila.
A report by the Commons Network and civil society partners shows that the pharmaceutical industry’s wish list for the TTIP is detrimental for public health, will increase the cost of medicines and undermines democratic processes
Le conseiller fédéral suisse Johann Schneider-Ammann a laissé entendre samedi dans la presse alémanique que la question de la protection des brevets pourrait retarder l’accord de libre-échange avec l’Inde.
Nearly two-thirds of Canadians oppose longer patents for brand-name drugs under a proposed trade deal with the European Union, according to a poll commissioned by the Council of Canadians.
Following the public outcry over the EU’s demands for stringent intellectual property rules that would dramatically raise medicines prices in India, you would expect the EU to think twice about making similar demands in future trade agreements. Yet, this is precisely what is going on now in the negotiations for a free trade agreement between the EU and Thailand.
There are apprehensions that TTIP would prevent Indian pharma companies to come to market with the same products - they would need to pass through several rounds of additional tests. As a result, prices will move up significantly.
Leaked details of free trade negotiations between New Zealand and the United States show the two countries are in stark opposition on a number of key areas.
Since announcing the Comprehensive Economic and Trade Agreement (CETA) two weeks ago Harper’s Conservatives have repeatedly labelled those questioning the deal as “anti-trade”. But this Canada-European Union accord is one part trade and four parts ‘corporate bill of rights’.
The federal government won’t release internal documents that may predict potential higher drug costs for Canadians under new patent rules agreed to in the free-trade deal with Europe, Trade Minister Ed Fast says.
The far reaching provisions of the Comprehensive Economic and Trade Agreement between Canada and the European Union will have considerable impact on Canada’s IP regime.
The struggle for access to medicine presents a legal and ethical minefield for rich and poor countries alike—one that is being fought out as humanitarians challenge corporations over intellectual property rights.
India is facing an onslaught of political pressure from the U.S. government and pharmaceutical industry in retaliation for the country’s entirely legal actions to limit abusive patenting practices and increase access to affordable generic medicines
Thai trade representative Olarn Chaiprawat has given civil society groups a confirmation that "TRIPS-plus" and drug issues will not be included in the Thai-EU FTA negotiations.